Information  X 
Enter a valid email address

NOVARTIS N ORD (0QLR)

Date Time Source Announcement
16 Apr 2019 9:45 pm
GNW
AveXis data reinforce effectiveness of Zolgensma® in treating spinal muscular atrophy (SMA) Type 1
15 Apr 2019 9:05 pm
GNW
Novartis announces FDA filing acceptance and Priority Review of brolucizumab (RTH258) for patients with wet AMD
11 Apr 2019 6:15 am
GNW
Sandoz drives differentiated portfolio with deal to commercialize new treatment for Opioid-Induced Constipation in key European countries
09 Apr 2019 6:00 am
GNW
Novartis continues transformation into a leading medicines company with completion of the Alcon spin-off
04 Apr 2019 9:00 pm
GNW
Novartis updates on the migraine collaboration with Amgen
03 Apr 2019 6:15 am
GNW
Sandoz resubmits biosimilar pegfilgrastim application to US FDA
02 Apr 2019 6:15 am
GNW
Novartis first-in-class Cosentyx® approved in China for psoriasis patients
01 Apr 2019 9:05 pm
GNW
AveXis expands world-leading gene therapy manufacturing capacity with purchase of advanced biologics therapy manufacturing campus in Longmont, Colorado
  6:15 am
GNW
Novartis adds clinical and preclinical anti-inflammatory programs to portfolio with acquisition of IFM Tre
26 Mar 2019 11:33 pm
GNW
Novartis receives FDA approval for Mayzent® (siponimod), the first oral drug to treat secondary progressive MS with active disease
22 Mar 2019 6:00 am
GNW
Novartis plans for Alcon spin-off on April 9, 2019
18 Mar 2019 6:15 am
GNW
Alcon Announces Acquisition of PowerVision, Inc.
14 Mar 2019 4:30 pm
GNW
Novartis joins the Global Chagas Disease Coalition and also announces first multinational, prospective, randomized study in people with chronic Chagas cardiomyopathy
  6:15 am
GNW
Novartis announces change in Sandoz leadership
10 Mar 2019 11:36 pm
GNW
Three winners of 2019 Sandoz Healthcare Access Challenge (HACk) are announced at SXSW
05 Mar 2019 6:15 am
GNW
Novartis Cosentyx® shows superior improvements in psoriasis patients' quality of life versus Janssen's IL-23 Stelara®*
04 Mar 2019 6:15 am
GNW
Novartis data confirm rapid response and high efficacy of Cosentyx® in psoriasis patients for first time in China
28 Feb 2019 12:50 pm
GNW
Novartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General Meeting
25 Feb 2019 10:55 pm
GNW
Novartis issues summary financial information for the Alcon eye care business ahead of shareholder vote on proposed spin-off
  6:15 am
GNW
Novartis to pursue transformational therapy to reduce risk of cardiovascular disease in people living with elevated levels of inherited lipoprotein(a)
13 Feb 2019 9:23 pm
GNW
Novartis receives FDA approval for Egaten® for the treatment of fascioliasis, a neglected tropical disease
30 Jan 2019 6:00 am
GNW
Novartis delivered strong sales growth with core margin expansion, built leading advanced therapy platforms and focused the company in 2018
08 Jan 2019 6:15 am
GNW
Novartis investigational therapy crizanlizumab (SEG101) receives FDA Breakthrough Therapy designation for the prevention of vaso-occlusive crises in sickle cell disease
07 Jan 2019 10:02 pm
GNW
Sandoz and Pear Therapeutics Announce US Launch of reSET-OTM to Help Treat Opioid Use Disorder
21 Dec 2018 1:53 pm
GNW
Novartis successfully completes acquisition of Endocyte
20 Dec 2018 4:00 pm
GNW
Novartis announces offer to acquire CellforCure to expand manufacturing capacity for innovative cell and gene therapies
  6:00 am
GNW
Novartis announces new CEO of Oncology Business Unit
19 Dec 2018 6:15 am
GNW
Sandoz enters into commercialization and supply agreement for insulin biosimilars, anticipating growing demand as diabetes burden rises
  6:10 am
GNW
Alcon Announces Acquisition of Tear Film Innovations, Inc.
13 Dec 2018 6:15 am
GNW
Novartis receives European Commission approval for self-administration of Xolair® across all indications
10 Dec 2018 8:42 pm
GNW
Sandoz Inc. and Pear Therapeutics Obtain FDA Clearance for reSET-O(TM) to Treat Opioid Use Disorder
08 Dec 2018 1:00 pm
GNW
Novartis data demonstrates consistent efficacy and tolerability of Kisqali® combination therapy in HR+/HER2- advanced breast cancer in patients with difficult-to-treat visceral disease
06 Dec 2018 3:30 pm
GNW
Novartis investigational BYL719 (alpelisib) plus fulvestrant consistently improved PFS in patients with PIK3CA mutated HR+/HER2- advanced breast cancer in new SOLAR-1 analyses
03 Dec 2018 6:15 am
GNW
Novartis announces FDA filing acceptance and Priority Review of AVXS-101, a one-time treatment designed to address the genetic root cause of SMA Type 1
02 Dec 2018 3:15 pm
GNW
Real-world data show Novartis drug Revolade® improves outcomes for ITP patients compared to other second-line therapies
01 Dec 2018 7:30 pm
GNW
Novartis announces longer-term analyses from pivotal Kymriah® trials that showed durable responses are maintained in patients with advanced blood cancers
  3:15 pm
GNW
Novartis announces new crizanlizumab (SEG101) data analysis in sickle cell disease, and investment in SENTRY clinical program
29 Nov 2018 6:15 am
GNW
Novartis announces EU approval of Gilenya® for children and adolescents with MS, making it the first and only oral disease-modifying treatment for these patients in Europe
27 Nov 2018 6:15 am
GNW
Sandoz receives eighth European Commission approval for a biosimilar with Ziextenzo® (pegfilgrastim)
  6:00 am
GNW
Alcon to highlight its vision, strategy and benefits as a standalone company to investors and analysts in New York and London
23 Nov 2018 6:15 am
GNW
Novartis announces landmark EU approval for one-time gene therapy Luxturna® to restore vision in people with rare inherited retinal disease
20 Nov 2018 1:15 pm
GNW
Novartis rises to second place in 2018 Access to Medicine Index
16 Nov 2018 9:30 pm
GNW
FDA approves Novartis drug Promacta® for first-line SAA and grants Breakthrough Therapy designation for additional new indication
  1:09 pm
GNW
Novartis receives positive CHMP opinion to expand Kisqali® combination therapy to all women with HR+/HER2- locally advanced or metastatic breast cancer
13 Nov 2018 9:28 pm
GNW
Alcon files initial Form 20-F registration statement with SEC for proposed spinoff; plans investor days in New York and London
11 Nov 2018 4:45 pm
GNW
New Novartis study supports Entresto as foundational HFrEF therapy and in-hospital initiation in appropriate stabilized heart failure patients
05 Nov 2018 6:00 am
GNW
Novartis R&D update highlights industry leading development pipeline including potential blockbusters and advanced therapy platforms
02 Nov 2018 10:00 pm
GNW
Sandoz decides not to pursue US biosimilar rituximab; will focus on robust biosimilar portfolio for unmet access and sustainability needs
  9:15 pm
GNW
Novartis data at ASH and SABCS show strength of pipeline and portfolio in hematology and oncology
31 Oct 2018 4:30 pm
GNW
Sandoz receives US FDA approval for biosimilar Hyrimoz(TM) (adalimumab-adaz)
29 Oct 2018 6:15 am
GNW
Novartis announces clinical collaboration with Pfizer to advance the treatment of NASH
27 Oct 2018 3:08 pm
GNW
Two-year data for Novartis brolucizumab reaffirm superiority versus aflibercept in reducing retinal fluid in patients with nAMD
26 Oct 2018 6:15 am
GNW
Novartis receives approval for Cosentyx® label update in Europe to include dosing flexibility in psoriatic arthritis
23 Oct 2018 6:15 am
GNW
Alcon to develop SMART Suite digital health platform for cataract surgery
22 Oct 2018 11:30 pm
GNW
Novartis announces Lancet publication of pioneering study in migraine prevention showing efficacy of Aimovig® where other treatments have failed
  8:15 am
GNW
Novartis COMBI-AD study of Tafinlar® + Mekinist® continues to demonstrate relapse free survival benefit in patients with BRAF V600-mutant stage III melanoma
20 Oct 2018 3:30 pm
GNW
Novartis investigational BYL719 (alpelisib) plus fulvestrant nearly doubles median PFS in patients with PIK3CA mutated HR+/HER2- advanced breast cancer compared to fulvestrant alone
19 Oct 2018 3:00 pm
GNW
Novartis phase II GEOMETRY mono-1 trial of investigational medicine capmatinib (INC280) shows positive results in patients with MET mutated advanced NSCLC
  6:15 am
GNW
Novartis announces presentation of new Lutathera® NETTER-1 data at ESMO demonstrating significant improvement in PFS regardless of baseline liver tumor burden
18 Oct 2018 6:02 am
GNW
Novartis announces planned acquisition of Endocyte to expand expertise in radiopharmaceuticals and build on commitment to transformational therapeutic platforms
 
Headlines
Top categories
Company finder
Forthcoming announcements

a d v e r t i s e m e n t